Qualcomm Inc. (QCOM) Falls 3.77% for February 05

Equities Staff  |

One of the S&P 500’s big losers for Friday February 05 was Qualcomm Inc. (QCOM). The company’s stock fell 3.77% to $43.94 on volume of 7.58 million shares.

The stock opened the day at 45.45 and traded between a low of $43.77 and a high of $45.60. The stock finished the day down $1.7222 per share. Qualcomm Inc. has an average daily volume of 14.27 million and a total float of 1.5 billion shares. The 50-day SMA for Qualcomm Inc. is $48.03 and its 200-day SMA is $57.38. The high for the stock over the last 52 weeks is $74.09 and the low is $42.88.

Qualcomm Inc develops digital communication technology called CDMA (Code Division Multiple Access), & owns intellectual property applicable to products that implement any version of CDMA including patents, patent applications & trade secrets.

Qualcomm Inc. is centered in San Diego, CA, and has 33,000 employees. Today’s trading day leaves the company with a market cap of $66.04 billion. The company has a P/S ratio of n/a, P/B ratio of 1.87, and a n/a.

For a complete fundamental analysis analysis of Qualcomm Inc., check out Equities.com’s Stock Valuation Analysis report for QCOM. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The S&P 500 represents the industry standard for large-cap indices. While the Dow Jones Industrial Average (DJIA) may be the most visible stock market index in the country, the S&P 500 has long been relied on by industry insiders and fund managers as the more reliable gauge of portfolio performance.

While the DJIA is price-weighted and only includes 30 stocks, the S&P 500 uses a weighting system that factors in market cap and the size of a company’s free float while including some 500 stocks for a more comprehensive look at the broader markets’ performance. Its performance is far more representative of the large- and mega-cap stocks for any period of time.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer



Symbol Last Price Change % Change










World Economic Forum at Davos 2019 - Frank Ricotta CEO BurstIQ

Matt Bird sits down with Frank Ricotta, CEO BurstIQ, at the World Economic Forum at Davos 2019

Emerging Growth

IMV Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.